Clinically stable HIV-infected patients receiving antiretroviral therapy containing stavudine 40 mg twice daily with a plasma HIV RNA < 200 copies/ml for at least 6 months were randomized to maintain stavudine 40 mg twice daily ( d4T40 arm ) , to reduce to 30 mg twice daily ( d4T30 arm ) , or to switch from d4T to tenofovir ( TDF arm ) .
